Head to head
Neurocrine Biosciences vs Takeda Pharmaceutical
Side-by-side on the measures that matter, with a plain-English read. Full detail: NBIX · TAK
NBIX
Neurocrine Biosciences
150.57-3.84%
1-year price shape — +8% over the period
Quant Rating C · 51/100
vs
TAK
Takeda Pharmaceutical
21.77+1.68%
1-year price shape — +57% over the period
Quant Rating C · 90/100
1-year performance, rebased to 100
Takeda Pharmaceutical edges it on the scoreable measures. Takeda Pharmaceutical has the highest Quant Rating (90); Takeda Pharmaceutical has done best over the past year (+57%); Takeda Pharmaceutical pays the highest dividend yield.
| NBIX | TAK | |
|---|---|---|
| Snapshot | ||
| Sector | Drug Manufacturers - Specialty & Generic | -- |
| Last price | 150.57 | 21.77 |
| Change today | -3.84% | +1.68% |
| 1-year return | +8.3% | +57.5% |
| Market cap | $15.24B | $69.76B |
| 52-week range | 122.14 – 186.12 | 13.92 – 22.07 |
| Valuation | ||
| P/E (TTM) | 22.34 | 311.00 |
| P/E percentile, own 5-yr range | 8th | 100th |
| P/B | 3.93 | 1.50 |
| Dividend yield | 0.00% | 1.44% |
| Profitability & growth | ||
| EPS (TTM) | 4.67 | -0.30 |
| Net profit (TTM) | $472.69M | $-970.94M |
| Revenue (TTM) | $3.70B | $4.69T |
| Provider revenue period date | 2026-09-29 | 2026-09-29 |
| Revenue growth (YoY) | +41.2% | +6.7% |
| Gross margin | 97.7% | 65.8% |
| Operating margin | 24.6% | 14.3% |
| Net margin | 19.0% | 0.9% |
| Free cash flow (TTM) | $1.04B | $433.95B |
| Provider cash-flow period date | 2026-09-29 | 2026-09-29 |
| Ownership & sentiment | ||
| Institutional ownership | 102.3% | 51.3% |
| Insider activity (12mo) | 16 buy / 30 sell | 19 buy / 31 sell |
| Short interest (% of float) | 5.8% | 0.1% |
| Analyst consensus | 84% buy / 16% hold (19) | 100% buy (1) |
| Analyst price target | $207 (+38%) | $50 (+132%) |
| StockVane view | ||
| StockVane Quant Rating | C (51) | C (90) |
| Company | ||
| Employees | 2,000 | 47,029 |
| Founded | 1992 | 1781 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.